欧林生物向港交所主板递交上市申请；罗氏回应流感特效药需求上升 | 医药早参

Group 1 - Eulin Bio submitted an application for H-share listing on the Hong Kong Stock Exchange, marking a significant step towards capitalizing and internationalizing the company [1] - The listing aligns with the current trend of pharmaceutical companies going public in Hong Kong, which may enhance A-share valuation elasticity in the short term and inject capital for R&D and global expansion in the long term [1] Group 2 - Alibaba Health reported a total revenue of 16.697 billion yuan, a year-on-year increase of 17.0%, and a net profit of 1.266 billion yuan, up 64.7% [2] - The core growth driver for Alibaba Health is attributed to the increase in self-operated business revenue, which reached 14.380 billion yuan, growing by 18.6% year-on-year [2] Group 3 - Eucan Vision Bio's OT-702, a biosimilar to EYLEA, received approval from the National Medical Products Administration for treating adult patients with neovascular age-related macular degeneration and diabetic macular edema [3] - The approval provides more treatment options for patients in China and is expected to boost the company's stock price in the short term while supporting long-term valuation [3] Group 4 - Roche has initiated a response plan to increase production and supply of its flu treatment, Tamiflu, to the Chinese market amid rising demand during the flu season [4] - This response highlights the importance of the Chinese market and the ongoing supply-demand imbalance for flu treatments [4] Group 5 - Boya Bio received a drug registration certificate for Tetanus Human Immunoglobulin from the National Medical Products Administration, adding to its product pipeline [5] - The approval is expected to enhance the company's R&D enthusiasm, although it is not anticipated to significantly impact the company's operating performance in 2025 [5]